Our vision:
We are building a leading biotech company specializing in acoustic-mediated therapies, developing ground-breaking solutions to enable and enhance the efficacy of medicines across an expanding range of therapeutic areas with a high unmet medical need, for the benefit of patients
Development areas
Focus on Oncology
Enabling precisice and enhanced delivery of standard of care medication for cancer treatment
Platform expansion
We have a disease agnostic product, and continuously investigate potential new areas where ACT can be utilized
Latest company news:
-
EXACT-Tx publishes 2023 Annual Report
The Annnual Report for 2023 was published on April 18, 2024
-
Poster presented at AACR
Additional promising clinical data from EXACT Therapeutics’ ongoing ACTIVATE study presented at AACR Annual Meeting
-
EXACT at Bio-Europe 2024
CEO, Per Walday, presented EXACT Therapeutics at the BIO-Europe conference in Barcelona on Marchc 18
-
Successful placement of NOK 25 million share issue
On November 30, EXACT Therapeutics announced that a NOK 25 million share issue has been completed.
Our technology
The Key differentiation of ACT® is:
ACT® has a biomechanical mode of action to increase the uptake of co-administered drugs from blood vessels into the surrounding (cancer) tissue, without damaging the cells within the capillary walls; unlike sonoporation, ACT® does not create holes in the epithelial cell membranes of the capillary wall.
With ACT®, the drug can reach IOO microns which is 10 layers of cells away from capillary with an ongoing pump effect that lasts for minutes.
Reproducible and signifcant uptake through targeted delivery into tumours and across the blood brain barrier (BBB).
A very strong toxicology package: including most recently, in relation to BBB opening where no extravasation of red blood cells was observed throughout the ACT® procedure in a preclinical rodent model.
Uses a bespoke dual frequency transducer with a standard ultrasound scanner to activate and enhance the clusters at the target tumour site. Compatible with existing ultrasound systems widely available in clinics/hospitals worldwide.
No drug reformulation required.
ACT® relies on ultrasound settings well within safe and approved ranges.
State of the art navigation system in development to ensure ACT® is delivered accurately at a targeted site
